Literature DB >> 29893235

Non-alcoholic fatty liver disease and the interface between primary and secondary care.

Emmanuel A Tsochatzis1, Philip N Newsome2.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) has a prevalence of 25-30% in unselected populations and has become the main reason for referrals to hepatology services. From the perspective of liver disease, NAFLD has a high prevalence but low severity. Screening studies in people at risk for NAFLD have shown a prevalence of advanced fibrosis of 5%, which underlines the need for robust pathways for risk stratification in primary care, with subsequent referrals as required. In this Review, we discuss the interface between primary and secondary care with regards to risk stratification and management of patients with NAFLD. We focus on selected issues of epidemiology and natural history and discuss the burden of disease in primary care, the evidence on screening for NAFLD, the rationale for testing for advanced fibrosis, and the optimal management of the disease in primary care.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29893235     DOI: 10.1016/S2468-1253(18)30077-3

Source DB:  PubMed          Journal:  Lancet Gastroenterol Hepatol


  25 in total

Review 1.  Defining comprehensive models of care for NAFLD.

Authors:  Manuel Romero-Gómez; Jörn M Schattenberg; Jeffrey V Lazarus; Quentin M Anstee; Hannes Hagström; Kenneth Cusi; Helena Cortez-Pinto; Henry E Mark; Michael Roden; Emmanuel A Tsochatzis; Vincent Wai-Sun Wong; Zobair M Younossi; Shira Zelber-Sagi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-25       Impact factor: 46.802

Review 2.  Lytic cell death in metabolic liver disease.

Authors:  Jérémie Gautheron; Gregory J Gores; Cecília M P Rodrigues
Journal:  J Hepatol       Date:  2020-04-13       Impact factor: 25.083

Review 3.  Apoptosis and necroptosis in the liver: a matter of life and death.

Authors:  Robert F Schwabe; Tom Luedde
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-12       Impact factor: 46.802

4.  Advanced liver fibrosis and the metabolic syndrome in a primary care setting.

Authors:  Andrew D Schreiner; Jingwen Zhang; Valerie Durkalski-Mauldin; Sherry Livingston; Justin Marsden; John Bian; Patrick D Mauldin; William P Moran; Don C Rockey
Journal:  Diabetes Metab Res Rev       Date:  2021-04-09       Impact factor: 4.876

5.  The Association of Fibrosis-4 Index Scores with Severe Liver Outcomes in Primary Care.

Authors:  Andrew D Schreiner; William P Moran; Jingwen Zhang; Sherry Livingston; Justin Marsden; Patrick D Mauldin; David Koch; Mulugeta Gebregziabher
Journal:  J Gen Intern Med       Date:  2022-01-19       Impact factor: 6.473

6.  Identifying Patients at Risk for Fibrosis in a Primary Care NAFLD Cohort.

Authors:  Andrew D Schreiner; Sherry Livingston; Jingwen Zhang; Mulugeta Gebregziabher; Justin Marsden; David G Koch; Chelsey A Petz; Valerie L Durkalski-Mauldin; Patrick D Mauldin; William P Moran
Journal:  J Clin Gastroenterol       Date:  2021-07-22       Impact factor: 3.062

Review 7.  Fighting liver fat.

Authors:  David Koeckerling; Jeremy W Tomlinson; Jeremy F Cobbold
Journal:  Endocr Connect       Date:  2020-07       Impact factor: 3.335

8.  Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Chiara Dell'Unto; Mara Volpentesta; Raffaele Antonelli-Incalzi; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2018-11-21       Impact factor: 5.742

9.  Validation of a two-step approach combining serum biomarkers and liver stiffness measurement to predict advanced fibrosis.

Authors:  Hideki Fujii; Masaru Enomoto; Shinya Fukumoto; Tatsuo Kimura; Yuji Nadatani; Shingo Takashima; Atsushi Hagihara; Sawako Uchida-Kobayashi; Akihiro Tamori; Naoki Nishimoto; Norifumi Kawada
Journal:  JGH Open       Date:  2021-06-10

10.  Embedding assessment of liver fibrosis into routine diabetic review in primary care.

Authors:  Dina Mansour; Allison Grapes; Marc Herscovitz; Paul Cassidy; Jonathan Vernazza; Andrea Broad; Quentin M Anstee; Stuart McPherson
Journal:  JHEP Rep       Date:  2021-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.